Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

Presentation ESC 2025

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

Presenter: Duk-Woo Park

August 31, 2025

Presentation TCT 2024

Pro

Presenter: Duk-Woo Park

October 28, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

News Daily News

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

Yael L. Maxwell

March 01, 2024

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

Presentation TCT 2023

DAPT Duration: Unsettled or Case Closed?

Presenter: Duk-Woo Park

October 24, 2023

Presentation ESC 2023

Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided PCI: The OCTIVUS Randomized Clinical Trial

Presenter: Duk-Woo Park

August 28, 2023

News Conference News ESC 2022

Routine Functional Testing Unnecessary After Stenting: POST-PCI

Yael L. Maxwell

September 06, 2022

News Daily News

Unplanned PCI Rare After TAVI, but Operators Get Good Results

Michael O'Riordan

January 18, 2021

News Daily News

Across Europe, Data Confirm ‘Missing STEMIs’ in COVID-19 Era

Caitlin E. Cox

November 09, 2020

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

Presentation TCT 2019

TICAKOREA: A Randomized Trial of Ticagrelor vs. Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management

Presenter: Duk-Woo Park

September 28, 2019

Presentation TCT 2018

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

Presenter: Dominick J. Angiolillo, Elmir Omerovic, Duk-Woo Park

September 23, 2018

Presentation TCT 2018

Long-Term Outcomes of LM PCI vs CABG: New Insights From the MAIN-COMPARE and IRIS-MAIN Registries

Presenter: Raj Makkar, Patrick W. Serruys, Duk-Woo Park

September 23, 2018

Presentation TCTAP 2018

OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients

Presenter: Duk-Woo Park

April 28, 2018

Presentation TCT 2017

Exploring Diversity and Generalizability of EXCEL/NOBLE II: IRIS-MAIN

Presenter: Antonio Colombo, David E. Kandzari, Duk-Woo Park

October 31, 2017

Presentation TCT 2017

Severe Calcified Coronary Lesions: The Next Target

Presenter: Gary S. Mintz, Seung-Jung Park, Duk-Woo Park

October 29, 2017

Advertisement

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

Pro

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

DAPT Duration: Unsettled or Case Closed?

Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided PCI: The OCTIVUS Randomized Clinical Trial

Routine Functional Testing Unnecessary After Stenting: POST-PCI

Unplanned PCI Rare After TAVI, but Operators Get Good Results

Across Europe, Data Confirm ‘Missing STEMIs’ in COVID-19 Era

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

TICAKOREA: A Randomized Trial of Ticagrelor vs. Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

Long-Term Outcomes of LM PCI vs CABG: New Insights From the MAIN-COMPARE and IRIS-MAIN Registries

OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients

Exploring Diversity and Generalizability of EXCEL/NOBLE II: IRIS-MAIN

Severe Calcified Coronary Lesions: The Next Target

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content